Safety and efficacy of Daclatasvir and Asunaprevir combination therapy for hemodialyzed patients with chronic hepatitis C

Safety and efficacy of Daclatasvir and Asunaprevir combination therapy for hemodialyzed patients with chronic hepatitis C - Daclatasvir and Asunaprevir therapy for hemodialyzed ptatients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000016355

Enrollment

100

Registered

2015-01-28

Start date

2015-01-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemodialyzed patients with chronic hepatitis C

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: hemodialyzed patients with chronic hepatitis C

Exclusion criteria

Exclusion criteria: 1 patients with heart failure 2 patients with decompensated cirrhosis 3 patients with allergic to NS5A inhibitor or HCV PI inhibitor 4 patients with HCC or other malignant disease

Design outcomes

Primary

Measure	Time frame
Sustained virological response adverse events	—

Countries

Japan

Contacts

Public ContactGoki Suda

Graduate School of Medicine,Hokkaido University Department of Gastroenterology and Hepatology

gsudgast@pop.med.hokudai.ac.jp011-716-2111

Outcome results